<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806286</url>
  </required_header>
  <id_info>
    <org_study_id>CS7017-A-U202</org_study_id>
    <nct_id>NCT00806286</nct_id>
  </id_info>
  <brief_title>Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase 2 Randomized Study of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-Na√Øve Subjects With Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects
      with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in
      combination with carboplatin and paclitaxel to evaluate safety. In the Phase 2 portion of the
      study, subjects will receive study drug (CS-7017) or placebo in combination with carboplatin
      and paclitaxel to evaluate effectiveness and safety. The study will find out if adding
      CS-7017 to carboplatin and paclitaxel will be safe and improve progression free survival in
      subjects with metastatic non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate</measure>
    <time_frame>week 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival</measure>
    <time_frame>end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Metastatic Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CS-7017 with Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS7017 tablets</intervention_name>
    <description>CS7017 tablets, strength 0.25mg, two tablets, two times daily for twenty-five to thirty months</description>
    <arm_group_label>CS-7017 with Paclitaxel and Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV, 200mg/m2, once every three weeks for up to 18 weeks</description>
    <arm_group_label>CS-7017 with Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_label>Paclitaxel and Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV, AUC of 6, once every three weeks for up to 18 weeks</description>
    <arm_group_label>CS-7017 with Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_label>Paclitaxel and Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Placebo tablets matching CS-7017 tablets</description>
    <arm_group_label>Paclitaxel and Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic (stage IV) NSCLC with no
             significant pleural effusion or pleural involvement from the tumor

          -  Age greater than or equal to 18 years

          -  Adequate organ and bone marrow function

        Exclusion Criteria:

          -  Any prior systemic therapy for NSCLC

          -  Major surgical procedure or other investigational agents within 4 weeks before study
             enrollment

          -  Need for concomitant use of other thiazolidinediones during the study

          -  History of any of the following conditions within 6 months prior to initiating study
             treatment: Diabetes mellitus requiring treatment with insulin or sulfonylureas or TZDs
             agents; Myocardia infarction with significant impairment of cardia function;
             Malabsorption syndrome, chronic diarrhea, inflammatory bowel disease or partial bowel
             obstruction;

          -  Clinically active brain metastases, uncontrolled seizure disorder; spinal cord
             compression or carcinomatous meningitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ. Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois Hematology/Oncology</name>
      <address>
        <city>Centralia</city>
        <state>Illinois</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology-Oncology</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor View Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>62801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton Hershey Cancer Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidwai Memorial Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pentagon Research</name>
      <address>
        <city>Aundh</city>
        <state>Maharashtra</state>
        <zip>411007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Super Specialty Hospital</name>
      <address>
        <city>Nashik</city>
        <state>Mumbai Naka</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemato-Oncology Clinic, Vedanta</name>
      <address>
        <city>Gujarat</city>
        <state>Navrangpura, Ahmedabad</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625 107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orchid Nursing Home</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Specialty Hospital</name>
      <address>
        <city>Chennai</city>
        <zip>600035</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noble Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Chemioterapii ZOZ MSWiA</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital im. Prof. Alfresa Sokolowskiego</name>
      <address>
        <city>Szczecin</city>
        <zip>70-891</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncomed SRL</name>
      <address>
        <city>Timisoara</city>
        <state>Judet Timis</state>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Municipal Ploiesti</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Prof. Dr. Alexandru Trestioreanu</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Prof. Dr. Ion Chiricuta</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Prof. Dr. Ion Chiricuta</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul de Oncologie Medicala</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <disposition_first_submitted>March 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 11, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 18, 2013</disposition_first_posted>
  <last_update_submitted>March 15, 2013</last_update_submitted>
  <last_update_submitted_qc>March 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Efatutazone</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

